Skip to main navigation Skip to search Skip to main content

Estimating Socio-Economic Status for Alzheimer’s Disease Trials

  • Dorene M. Rentz
  • , J. D. Grill
  • , D. P. Molina-Henry
  • , G. A. Jicha
  • , M. S. Rafii
  • , A. Liu
  • , R. A. Sperling
  • , P. S. Aisen
  • , R. Raman

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Introduction: Metrics of a participant’s socioeconomic status (SES) are not routinely collected or standardized in clinical trials. This omission limits the ability to evaluate the generalizability of trial results and restricts clinicians from confidently interpreting the efficacy of new treatments across important sub-populations. Methods: We adapted an SES measure of social disparity; the Hollingshead Two Factor Index of Social Position, which combines education and occupation into a single metric. We modernized the 1965 occupations to reflect the 2017 careers tabulated by the US Bureau of Labor Statistics. We currently use this adapted measure in Alzheimer’s Clinical Trials Consortium studies. Results: We present the revised table of occupations. We found that the collection of SES data using the modified Hollingshead was feasible in a multi-site clinical trial and scores were distributed across all SES strata. Discussion: The modified Hollingshead provides a standardized method for collecting SES information, enabling data aggregation, monitoring, and reporting.

Original languageEnglish
Pages (from-to)1418-1425
Number of pages8
JournalJournal of Prevention of Alzheimer's Disease
Volume11
Issue number5
DOIs
StatePublished - Oct 2024

Bibliographical note

Publisher Copyright:
© The Authors 2024.

Funding

The authors would like to thank the site principal investigators of AHEAD study along with their staff, participants and their study partners. We also thank the Alzheimer Therapeutic Research Institute (ATRI) and the Alzheimer Clinical Trial Consortium for making this data available. Funding: The Alzheimer’s Clinical Trials Consortium (ACTC) is supported through funding provided by the National Institute on Aging (U24AG057437). The AHEAD Study is conducted as a Public-Private Partnership of the Alzheimer’s Clinical Trial Consortium (ACTC), funded by the National Institute on Aging (R01AG061848, R01AG054029), Eisai Inc., the GHR Foundation and other philanthropists.

FundersFunder number
Alzheimer Clinical Trial Consortium
Alzheimer Therapeutic Research Institute
GHR Foundation
Eisai Incorporated
National Institute on AgingU24AG057437
National Institute on Aging
Alzheimer’s Clinical Trial ConsortiumR01AG054029, R01AG061848

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Socioeconomic status
    • clinical trials
    • socioeconomic indicators

    ASJC Scopus subject areas

    • Clinical Neurology
    • Psychiatry and Mental health

    Fingerprint

    Dive into the research topics of 'Estimating Socio-Economic Status for Alzheimer’s Disease Trials'. Together they form a unique fingerprint.

    Cite this